

In vivo antimalarial activity of the crude leaf extract of *Combretum molle* against *Plasmodium berghei* in mice

Melkamu Adigo Shibeshi

Awi health department

Tezera Jemere Aragaw (✉ tezeraadis1982@gmail.com)

University of Gondar

Getnet Mequanint Adinew

University of Gondar

Engdaw Fentahun Enyew

University of Gondar

Research

Keywords: Antimalarial, *Combretum molle*, crude extract, *Plasmodium berghei*, sub-acute toxicity

Posted Date: February 8th, 2020

DOI: <https://doi.org/10.21203/rs.2.22912/v1>

License:   This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

1 *In vivo* antimalarial activity of the crude leaf extract of *Combretum molle*
2 against *Plasmodium berghei* in mice

3
4 Melkamu Adigo Shibeshi (MA)¹, Tezera Jemere Aragaw (TJ)², Getnet Mequanint
5 Adinew (GT)², and Engdaw Fentahun Enyew (EF)³

- 6 1. Awi zone health department, Awi zone, Ethiopia
7 2. Department of Pharmacology, College of Medicine and Health Sciences,
8 University of Gondar, Gondar, Ethiopia.
9 3. Department of human anatomy, College of Medicine and Health Sciences,
10 University of Gondar, Gondar, Ethiopia.

11 Corresponding Author: Tezera Jemere Aragaw

12 **Email addresses:**

13 MA: melkemelkadigo@yahoo.com

14 TJ: tezeraadis1982@gmail.com

15 GM: mequanint@yahoo.com

16 EF: engdaw212@gmail.com

17
18
19
20
21
22
23
24
25
26
27
28
29
30

31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61

Abstract

Background: Malaria is an infectious, hematologic disease causing death and illness in children and adults, especially in tropical countries. The aim of this study was to evaluate the antimalarial activity of *Combretum molle* extract *in vivo* assays against *Plasmodium berghei* in Swiss albino mice.

Methods: *Plasmodium berghei* a rodent malaria parasite was inoculated to healthy Swiss Albino mice age 6–8 weeks either sex, weight 20–33g. 100, 200 and 400mg/kg/day of Crude methanolic extract of *Combretum molle* were administered. Parameters such as Percent parasitemia, body weight, Body temperature, packed cell volume and survival time were then determined using standard tests. Data were analyzed using one-way ANOVA followed by the Post hoc Tukey HSD test with SPSS software version 24.0 and $P \leq 0.05$ considered as statistically significant.

Results: Chemosuppressive effect exerted by the crude extract ranged between 27-68%. The curative effect of the crude extract was in the range of 25-49% and prophylactic effect of the crude extract was in the range of 51–76.2%. The maximum effect in all tests on Chemosuppressive, curative, Prophylactic, prevention of weight loss, body temperature and packed cell volume and an increase in mean survival time was observed at higher doses of the crude extract.

Conclusion: From the present study it can be concluded that the crude extract of *Combretum molle* leaves has been shown promising antimalarial activity. This finding supports the traditional use of the plant for the treatment of malaria in Ethiopia. Thus, it could be considered as a potential source to develop safe, effective and affordable antimalarial agent.

Key Words: Antimalarial, *Combretum molle*, crude extract, *Plasmodium berghei*, sub-acute toxicity

62

63 **Background**

64 Malaria is an infectious, hematologic disease ^[1] causing death and illness in
65 children and adults ^[2]. Malaria is caused by single-cell Plasmodium species that
66 invade, grow and replicate in red blood cells in a cyclic pattern which makes it such
67 a deadly disease^[3, 4]. Malaria control requires prevention, primarily vector control,
68 and prompts treatment with effective antimalarial drugs ^[5]. Malaria is among the
69 most devastating and widespread tropical parasitic diseases in which most prevalent
70 in developing countries ^[6]. Antimalarial drug resistance results in a global
71 resurgence of malaria making a major threat to malaria control.^[7]

72 From the World Health Organization (WHO) 2018 malaria report 219 million cases
73 of malaria from 90 countries. The WHO African region with 200 million cases
74 (92%) in 2017, especially Sub-Saharan Africa suffers by far the greatest malaria
75 burden worldwide. Almost 93% of all deaths due to malaria in 2017 were from
76 Africa ^[8].

77 Seventy percent of malaria caused deaths occurring among the under five-year age
78 group. Nigeria, the Democratic Republic of the Congo, Burkina Faso and India
79 accounted for 47% of all malaria deaths globally ^[9]. *P. falciparum* species are
80 dominant in Africa and *P.vivax* infection is in Southeast Asia and South America
81 ^[10]. In pregnant, women *P. falciparum* causes infections because of parasite's
82 ability to massively sequester in the placenta and compromised immune status,
83 mainly in the first and second trimesters of pregnancy ^[11].

84 About 60% of the Ethiopian population is at risk of malaria with major
85 transmission seasons from June to December and remain responsible for a massive
86 burden of disease and death ^[12, 13].

87 **The experimental plant**

88 The Combretaceae is a large family of herbs, shrubs, and trees, comprising about 20
89 genera and 600 species with tropical distribution around the globe and centers of
90 diversity in Africa and Asia. Simple hairs of indumentum, multicellular or
91 glandular hairs secreting calcium oxalate and forming scales or present beneath
92 cuticle and making leaf blade surface verruculose and sometimes translucent

93 dotted. Leaves (opposite, sub opposite, whorled, spiraled, or alternate, usually
94 petiolate), flowers are unisexual or bisexual and the seed is usually one-seeded and
95 flattened ^[14].

96 Combretum is the largest and most widespread genus of Combretaceae which
97 comprises approximately 200-250 species. *Combretum molle* is a shrub or small,
98 graceful, deciduous tree, 3 - 13 m high, with a crooked or lean trunk, occasionally
99 swollen at the base, and up to 30 cm in diameter. *Combretum molle*
100 (R.Br.ex.G.Don) Engl and Diels are indigenous to Africa and are one of the
101 important medicinal species of the family ^[15]. Different parts of the *Combretum*
102 *molle* are widely used as a medicinal plant to treat various diseases such as
103 parasitic, protozoan and other infectious diseases ^[16].

104 The Fresh leaf is boiled in water and the decoction is drunk by a cup of tea which
105 was studied from Delanta (Amhara region), and Amaro District (Southern Nations
106 Nationalities People region). Probably leaves are the center of intermediary
107 metabolism leading to biologically active secondary metabolites ^[17, 18]. The *in vitro*
108 cell culture (K562S human monocyte infected with *P. falciparum* W2) study had
109 shown activity with an IC₅₀ value of 5.7 or 7.9µg/mL, respectively from 80%
110 methanol extract of leaves. Ethanol 90% extract of leaves, root bark or stem bark *in*
111 *vitro* cell culture with *P. falciparum* K1 showed activity with an IC₅₀ value of 4.0
112 µg/mL^[19].

113 Stem bark *in vitro* cell culture (Trophozoites of *P. falciparum*) of acetone fraction
114 showed activity with IC₅₀ value of 8.17µg/mL. MeOH extract of dried stem *in vitro*
115 cell culture with *Plasmodium falciparum* also showed activity with an IC₅₀ value of
116 1.25 µg/MI ^[20, 21].

117 **Methods**

118 **Plant Material**

119 Fresh leaves of *Combretum molle* were collected from “Tara Gedam”, Libo
120 Kemkem District, South Gondar Zone, Amhara region 85 Kilometer away from
121 Gondar city on December 13, 2018. The collected plant material was wrapped and
122 covered with plastic sheets during transportation. The specimen of the plant was
123 authenticated by a botanist, in the biology department, University of Gondar and

124 was deposited in the herbarium with a voucher specimen (No 001MAS) for future
125 reference.

126 **Preparations of crude methanolic extract**

127 The leaves of *C.molle* were washed with tap water gently to eliminate any dirt and
128 dried at ambient temperature, protected from light, reduced to an appropriate size
129 by hand compression and stored at ambient temperature until extraction. 1500g of
130 leaf powder of *C.molle* was weighed with electric balance and transferred to the
131 Erlenmeyer flasks and 80% methanol (one gram of *C.molle* powdered leaf to ten
132 milliliters of 80% methanol ratio) was added and agitated in between. After 72
133 hours of maceration extraction was performed using thick layers of 40 mesh gauze
134 and then filtered with Whatman filter paper no1 two times and 2nd extraction was
135 repeated after 72 hours of maceration and the 3rd extraction was repeated another
136 72 hours later (with a total of nine days). The extracts were combined and
137 concentrated by the dry oven at 40⁰C and the yield was determined and found to be
138 287g (19.13%) and stored in a refrigerator at 4⁰C until use ^[22].

139 **Phytochemical screening**

140 Secondary metabolites are classes of compounds that are known to show a curative
141 activity against several ailments in humans and then could explain the traditional
142 use of medicinal plants for the treatment of some illnesses. Complex structural
143 molecules such as alkaloids, Phenolic compounds, anthraquinones, resins,
144 saponins, steroids, and terpenoids are found in a more restricted distribution than
145 primary metabolites. They are not indispensable for the plant that contains them; at
146 least their metabolic functions have not been discovered yet^[23]. Standard qualitative
147 tests were employed to detect secondary metabolites ^[24 - 31].

148 **Animals and parasite**

149 Swiss albino mice weighing between 20 - 33g, 6 – 8 weeks of age and either sex
150 were purchased from the Ethiopian public health institute (EPHI) Addis Ababa.
151 The animals were kept in cages and housed in a standard animal house under a
152 natural 12/12h light-dark cycle at room temperature and maintained on a standard
153 pellet diet and water ad libitum. Before the experiment, they were acclimatized to
154 the test environment for one week. The care and handling of mice were according

155 to international guidelines for the use and maintenance of experimental animals [32,
156 33].

157 Chloroquine-sensitive malaria, *P. berghei* was obtained from EPHI in the
158 traditional medicine research department Addis Ababa and transported by infecting
159 the donor mice and maintained the parasite up to the main procedure of the study.

160 **Acute toxicity test**

161 Five mice weighing between 20 - 28 grams, 6-8weeks of age female sex were kept for one
162 week prior to dosing to acclimatize. One mouse was randomly taken for sighting study and
163 food but not water was withheld for 4 hours. Following the period of fasting, the mouse
164 was weighed and the crude methanolic extract of *C. molle* leaf 2000mg/kg body weight
165 was administered by the oral route. Strict observation within 30minutes and periodically
166 during the first 24 hours, with special attention given during the first 4 hours and daily
167 thereafter, for a total of 14 days. Changes in skin and fur, eyes, mucous membranes,
168 respiratory, autonomic and central nervous system changes, somatomotor activity and
169 behavior patterns were observed. Tremors, convulsions, salivation, diarrhea, lethargy, sleep
170 and coma were evaluated. But the mouse in the sighting test did not show any sign of
171 toxicity for four-days and the main toxicity doses of the remaining 4 mice for methanolic
172 crude extract were given and followed as usual for 14 days [32, 34].

173 **Subacute toxicity test**

174 The subacute toxicity study was conducted on 24 healthy adult female mice divided
175 into four groups of six each. The control group received solvent; the other three
176 groups were given 100, 200 and 400mg/kg/day of *C. molle* crude extract orally for
177 28 days. The mice were observed every two hours for toxic signs and their weights
178 were measured weekly for five weeks. On the 28th day, mice were anesthetized
179 with ketamine and sacrificed. Their Liver and kidneys were removed and weighed
180 [32, 35].

181 **Tissue processing**

182 Immediately removed liver and kidneys were placed in 10% formalin with
183 phosphate-buffered saline solution overnight at room temperature. After overnight
184 fixation, the tissues were dehydrated with increased concentration of alcohol: 70%,
185 80%, 90% for five and half hour, then cleared with xylene for seven hours. Finally,
186 the tissues were impregnated for six hours. Then, tissue blocks were prepared by

187 embedding with paraffin wax in a square metal plate and labeled. Tissue blocks
188 were sectioned with a thickness of 5µm using a rotary microtome. Strips of sections
189 were gently lowered into the surface of a warm water bath at 40°C for sections to
190 be floated, then mounted with coated egg albumin slides and the slides containing
191 paraffin wax within a slide holder were placed in an oven with a temperature of
192 60°C for 10-15 minutes until they become free of wax.

193 Sectioned tissues were placed in xylene to deparaffinize and hydrated with
194 decreasing alcohol concentrations, then stained with Hematoxyline for 5 minutes
195 and counterstained by using eosin for one minute. After washing in tap water, the
196 sections were dehydrated with increased alcohol concentration and cleared with
197 xylene.

198 Finally sections were mounted on microscopic slides by using Canada balsam
199 mount and cover slips and examined the tissue under the compound light
200 microscope with different objectives were taken a photo automatically with
201 magnification of x40 [36-38].

202 **Pharmacologic screening (4-day Suppressive test)**

203 *In vivo* evaluation of methanolic leaf crude extract of *C. molle* antimalarial activity
204 on rodent malaria parasite *P.berghei*. Donor *P. berghei* infected Swiss albino mice
205 (parasitemia of approximately 30%) were sacrificed by decapitation and, then
206 blood was collected through cardiac puncture with a sterile disposable needle and
207 syringe. The blood was diluted with sterile sodium chloride 0.9% in water in such a
208 way that 0.2ml of blood contained about 10⁷ infected RBCs and mice were infected
209 by 0.2ml blood suspension intraperitoneally which was expected to produce
210 steadily rising consistent infection of the required intensity in mice [35]. Then Mice
211 were randomly divided into five groups of six each, weighed, and maintained in a
212 standard diet. The doses of crude extract were adjusted from the safest dose of
213 acute-toxicity study and were 5%, 10%, and 20% (i.e. 100,200 and 400mg/kg) once
214 daily for 4 days. The fourth group received chloroquine base 25mg/kg (positive
215 control) and the fifth group was received solvent which contains 3ml of 96%
216 ethanol + 7ml of Tween 80 + 90ml of distilled water (negative control)[39, 40] and

217 administered by oral route using oral gavage, starting from 3 hours of parasite
218 inoculation.

219 **Determination of parasitemia**

220 On day 4 (96 hours) post-infection a drop of blood was collected from the mice by
221 vein section of the tail and transferred onto the edge of a microscopic slide and
222 drawn evenly across the second slide to make a thin blood film and allowed to dry
223 at room temperature, fixed with methanol, stained with 10% Giemsa stain for 15
224 minutes. Slides were viewed using light microscopy with oil immersion (1000 x
225 magnification). Percentage parasitemia was determined by counting the number of
226 PRBCs out of 200 RBCs in random fields of the microscope. Five fields of
227 approximately 200 cells counted and the parasitemia was calculated as the
228 percentage of the total RBCs containing PRBCs [41, 42]. The body weight, body
229 temperature, packed cell volume and mean survival time were determined for each
230 group arithmetically [40].

231 Percent parasitemia was calculated according to the following formula

$$232 \quad \% \text{ paristemia} = \frac{\text{Total number of PRBC}}{\text{Total number of RBC}} \times 100 \quad \text{Where:- PRBC: Parasitized red blood cells}$$

233 RBC: red blood cells

234 Average percentage of parasitemia suppression was calculated as follows:

$$235 \quad \text{Average \% of paristemia supression} = \frac{\text{Av. \% of parasit.in control} - \text{Av. \% of parasitemia in test}}{\text{Av. \% of parasitemia in control}} \times 100$$

236

Av = average

237 **Rane's (Curative) test**

238 Evaluation of the curative potential of methanolic leaf crude extract of *C. molle* was
239 carried out according to the method described by curative methods [43]. On Day 0,
240 standard inocula of about 10^7 infected erythrocytes were inoculated in mice
241 intraperitoneally and randomly divided into their respective groups weighed and
242 maintained in a standard diet. Seventy-two hours later they were dosed Crude
243 methanolic extract at 100,200 and 400mg/kg/day, Chloroquine base 25mg/kg/day
244 and solvent which were prepared from 3ml of 96% ethanol + 7ml of Tween 80 +
245 90ml of distilled water once daily for five days. Giemsa stained thin blood film
246 was prepared from the tail of each mouse daily for 5 days (day 3,4,5,6 & 7) to

247 monitor the parasitemia level. The body weight, body temperature, packed cell
248 volume and mean survival time were determined for each group arithmetically [40].

249 **The Repository (Prophylactic) Test**

250 In prophylactic test prior to infection, mice in the test groups (three groups with
251 100, 200 and 400mg/kg of crude extract) were administered once daily orally for
252 three days. The remaining two groups were administered with the standard drug
253 (chloroquine base 25 mg/kg) and vehicle (solvent 10ml/kg/day). On the fourth day,
254 a standard inoculum of *Plasmodium berghei* containing $\sim 1 \times 10^7$ infected
255 erythrocytes was administered intraperitoneally to each mouse. On the seventh day
256 of infection (seventy-two hours later), thin blood smears (Giemsa stained) were
257 prepared from the tail of each mouse by vein section. Percentage parasitemia as
258 well as the chemo suppression, body weight, body temperature, packed cell volume
259 and mean survival time were determined for each group arithmetically [43].

260 **Measurement of Packed Cell Volume (PCV)**

261 Packed cell volume (PCV) was measured to predict the effectiveness of the test
262 extract and fractions in preventing hemolysis resulting from increasing parasitemia
263 associated with malaria. Heparinized capillary tubes were used for the collection of
264 blood from the tail of each mouse. The capillary tubes were filled with blood up to
265 three-fourth of their volume and sealed at the dry end with sealing clay. The tubes
266 were then placed in a micro-hematocrit centrifuge, with the sealed end outwards
267 and centrifuged for 5 min at 12,000 rpm. The tubes were taken out of the centrifuge
268 and PCV was determined using a standard Micro-Hematocrit Reader [44, 45].

269 **Monitoring of body weight and temperature changes**

270 In Peter's test the bodyweight was measured one hour before parasite infection on
271 D0 and at the end of D3 after treatment completion, while the rectal temperature
272 was measured 1 hour before and 3 hours after parasite infection and then
273 consecutively for 4 days to monitor the consequence of plant extracts on mice's
274 body temperature. For Rane's test, the body weight and temperature were measured
275 three hours before infection on day 0 (D0) and consecutively for five during the
276 treatment period to establish the effect of plant drug on malarial mice. For the
277 prophylactic test, the body weight and temperature were measured three hours

278 before infection on day 0 (D0) and consecutively from D4–D7 after infection
279 period to establish the effect of plant extract on *P. bergeri* infected mice [46].

280 **Data quality control**

281 The quality of data was assured by using randomization during the grouping of
282 experimental animals. Unique codes were used for all frosted microscopic slides
283 during the preparation of blood smears. Parasitized red blood cells were counted
284 blindly by laboratory technologist (Medical laboratory technologist, MSc in
285 medical parasitology).

286 **Data analysis**

287 The results of the study were expressed as the mean \pm standard error of the mean
288 (M \pm SEM). Comparison of parasitemia and statistical significance was determined
289 by one-way ANOVA (a repeated measure of analysis of variance) descriptive
290 statistics followed by Post Hoc tests for multiple comparisons of Tukey HSD and
291 paired t-test was employed to test significance of the difference between initial and
292 final results within the same and in between groups using SPSS for window
293 (Version 24.0) statistical package. All data were analyzed at a 95% confidence
294 interval ($\alpha = 0.05$) was considered statistically significant [40].

295 **Results**

296 **Phytochemical screening**

297 The phytochemical screening of 80% methanol crude extract of *Combretum molle*
298 indicated the presence of alkaloids, cardiac glycosides, flavonoids, phenols,
299 saponins, tannins, and terpenoids.

300 **Acute oral toxicity test**

301 The acute oral toxicity study showed that no death and any sign of toxicity to mice
302 with an oral dose of 2000mg/kg of the crude extract of *C. molle* observed for two
303 weeks. Here it could be deduced that the lethal dose fifty (LD₅₀) was above
304 2000mg/kg per body weight. The bioactive constituents of the plant are safe for use
305 even though it is difficult to extrapolate the result to humans.

306 **Subacute toxicity study**

307 The crude extract of *C. molle* was administered for consecutive 28 days at doses of
308 100, 200 and 400mg/kg/day showed a mean loss of 1.01 ± 0.84 g ($p = 0.013$),

309 1.23±0.86g (P = 0.012), and 0.45±0.66g (P= 0.065) respectively. Mice treated
 310 with solvent gain a mean body weight of 3.05±0.95g.(See table 1).

311 **Table 1: Body weight of mice in subacute toxicity study of *C. molle* crude**
 312 **extract**

Treatment group	Body weight (g)					
	Initial weight	After 1 week	After 2 weeks	After 3 weeks	After 4 weeks	Body Wt. dif.
Control	28.44±0.97	31.52±0.72	31.45±0.68	31.47±0.54	31.48±0.62	3.05±0.95
CM100mg/kg	26.46±1.27	28.29±1.66	28.65±1.27	26.42±1.48	25.45±2.04	-1.01±0.84 ^{al}
CM200mg/kg	27.31±0.68	27.11±1.69	24.76±1.26	26.68±1.76	25.89±1.52	-1.23±0.86 ^{al}
CM400 mg/kg	27.47±0.84	27.43±1.04	24.60±0.63	26.70±1.18	26.73±0.90	-0.45±0.66

313 Results presented as mean ±SEM; n= 6; CM= *Combretum molle*

314
 315 The mean weight of kidney in subacute toxicity test at 100, 200 and
 316 400mg/kg/day was 0.17±0.02g (P= 0.945), 0.17±0.02g (P=0.945) and 0.13±0.01g
 317 (P= 0.180) respectively. There was no significant difference compared to negative
 318 control group (0.18±0.01g). (See table 2)

319 The mean weight of liver in subacute toxicity test at 100, 200 and 400mg/kg/day
 320 was 1.80±0.09g (P=0.242), 1.65±0.10g (P=0.028) and 1.55±0.10g (P=0.008)
 321 respectively. At doses 200mg/kg and 400mg/kg produced significant differences
 322 compared to negative control group (p<0.05 and p<0.01) respectively compared to
 323 the negative control 2.05±0.08g.(See table 2)

324 **Table 2: Absolute organ weight of mice during sub -acute toxicity study of**
 325 ***Combretum molle* crude extract**

Treatment group	Weight (g)	
	Kidney	Liver
Control	0.18±0.01	2.05±0.08
CM100mg/kg	0.17±0.02	1.80±0.09
CM200mg/kg	0.17±0.02	1.65±0.10 ^{a1}
CM400mg/kg	0.13±0.01	1.55±0.10 ^{a2}


326 Results presented as mean ±SEM; n= 6, ^a compared to control, ¹p<0.05, ²p<0.01
 327 CM= *Combretum molle*
 328
 329

330 **Result of histopathology of liver and kidney of mice**

331 **Effects of methanolic leaf extracts of *C. Molle* on histology of the liver and**
332 **kidney tissues.**

333 Microscopic examination of liver sections of mice treated with *C. molle* leaf crude
334 extract at 100, 200, and 400mg/kg/day showed the normal architecture of structural
335 units of the hepatic lobules, formed by cords of hepatocytes separated by hepatic
336 sinusoids. The central vein and portal area containing branches of hepatic artery,
337 bile duct and portal veins were maintained with their normal appearance similar to
338 the negative control (See figure 1A).

339 Microscopic examination of kidney sections of mice treated with *C. molle* leaf
340 crude extract at 100, 200, and 400mg/kg/day showed the normal architecture of
341 structural units of the Glomerulus, Urinary space, Proximal convoluted tubule,
342 Distal convoluted tubule, Macula densa, Vascular pole were maintained with their
343 normal appearance similar to the negative control (See figure 1B).



344 **A. Microscopic structure of liver** **B. Microscopic structure of kidney**
345 **Figure 1: Microscopic architectures of liver and kidney after histopathological**
346 **procedure (A=Negative control, B=100mg/kg, C=200mg/kg, and D=400mg/kg)**
347 **of *C. molle* crude methanolic extract.**

348 Liver: (CV=Central vein, H=Hepatocytes, E=Endothelial cells, S=sinusoids, K=Kupffer
349 cells)

350 Kidney: (G =Glomerulus, US=Urinary space, PCT=Proximal convoluted tubule,
351 DCT=Distal convoluted tubule, MD=Macula densa, VP=Vascular pole)

352 **Antimalarial suppressive test**

353 Antimalarial suppressive test of methanolic crude extract of *C. molle* leaf and
 354 chloroquine base against *P.berghei* infected mice resulted in reduced parasite load
 355 as compared to their respective negative control group. Methanolic crude extract at
 356 100, 200 and 400mg/kg/day and Chloroquine base at 25mg/kg/day showed 33.08,
 357 45.36 and 76.17 95.71 % parasitemia suppression respectively and the results were
 358 highly significant(P < 0.001) compared to the negative control group at day-4.(see
 359 table 3)

360 Methanolic leaf crude extract of *C. molle* leaf at 100, 200, 400mg/kg/day showed
 361 7.00 ±0.97 (P=0.988), 9.83 ±1.92 (P=0.571), 13.83 ±3.20 (P=0.049) and
 362 Chloroquine base at 25mg/kg/day showed 27.00 ±2.03 (P<0.001) days of mean
 363 survival time in four day suppressive test respectively. Chloroquine base at
 364 25mg/kg/day showed highly significant (P<0.001) in survival days compared to
 365 negative controls (5.67±0.49)(see table 3).

366 **Table 3: Mean Percent Parasitemia and mean percent parasitemia suppression**
 367 **and mean survival time of *P. berghei* infected mice treated with methanolic**
 368 **crude extract of *C. molle* leaf in the 4 day suppressive test.**

Extract	% Parasitemia	% Parasitemia Suppression	Mean survival time
CON	33.40±2.43	0.00	5.67±0.49
CM ₁₀₀	22.35 ±1.76	33.08 ^{a3d3e3}	7.00 ±0.97 ^{e3}
CM ₂₀₀	18.25 ± 2.27	45.36 ^{a3d1e3}	9.83 ±1.92 ^{e3}
CM ₄₀₀	7.96 ± 2.26	76.17 ^{a3b3c1}	13.83 ±3.20 ^{a1e2}
CQ25	1.43 ±0.75	95.71 ^{a3b3c3}	27.00 ±2.03 ^{a3b3c3d2}


369 Data are expressed as mean ± SEM; n = 6, CON = Control (solvent 10ml/kg), CM=
 370 crude methanolic extract, CF = Chloroform fraction of *Gardenia ternifolia*, CQ =
 371 chloroquine, % par supp= % parasitemia suppression, Numbers refer to dose in mg/kg.
 372 a, compared to neg. control; b, to 100mg/kg; c, to 200mg/kg; d, to 400 mg/kg; e, to
 373 CQ10mg/kg: 1p<0.05, 2p<0.01, 3p<0.001.

374 *Plasmodium berghei* infected mice treated in a suppressive test at 100mg/kg/day
 375 methanol crude extract loss mean body weight of 0.85 ±0.210g (p = 0.297),
 376 200mg/kg/day loss mean body weight of 1.97± 0.673g (P = 0.991), 400mg/kg/day loss
 377 mean body weight of 1.62±0.825g (P= 0.882), and Chloroquine base at 25mg/kg/day
 378 loss mean body weight of 0.17 ±0.099g (P= 0.050) and mice treated with solvent loss
 379 mean body weight of 2.29 ±0.339g. The extract of *C. molle* leaf prevented a loss of

380 body weight in infected mice at high doses. Small decrease in body weight was
 381 observed in Chloroquine treated group. (See figure 2A)

382 *Plasmodium berghei* infected mice treated in suppressive test at 100mg, 200mg,
 383 400mg /kg/day methanol crude extract and Chloroquine base at 25mg/kg/day decrease
 384 a mean body temperature of 0.82 ± 0.16 °C ($p = 0.106$), 0.52 ± 0.13 °C ($P = 0.003$),
 385 0.22 ± 0.17 °C ($P < 0.001$) and 0.05 ± 0.03 °C ($P < 0.001$) and mice treated with solvent
 386 decrease a mean body temperature of 1.35 ± 0.18 °C. The extract of *C.molle* leaf
 387 decreases a mean body temperature in infected mice from 200mg/kg/day ($P \leq 0.003$).
 388 (See figure 2B)

389 *Plasmodium berghei* infected mice treated in suppressive test at 100mg, 200mg,
 390 400mg /kg/day methanol crude extract and Chloroquine base at 25mg/kg/day loss a
 391 mean packed cell volume of 1.75 ± 0.63 % ($p = 0.795$), 1.25 ± 0.48 % ($P = 0.315$),
 392 0.80 ± 0.37 % ($P=0.60$) and 0.83 ± 0.17 % ($P= 0.050$) and mice treated with solvent loss
 393 a mean packed cell volume of 2.40 ± 0.40 %. The extract of *C.molle* leaf did not show
 394 a significant difference in a mean packed cell volume compared to the negative
 395 control. (See figure 2C)



396 **Figure 2: Showed effect of Crude methanolic extract of *C. molle* leaf in *P. berghei***
 397 **infected mice in Chemosuppressive test.** [CON = negative control (solvent 10ml/kg),
 398 CM= chloroform fraction, CQ = chloroquine, BWD0= body weight at day zero,
 399

400 BWD4= body weight at day 4, PCV= packed cell volume, numbers = dose in
401 mg/kg/day]

402 Methanolic crude extract in a curative test at 100, 200 and 400mg/kg/day and
403 Chloroquine base at 25mg/kg/day showed 43.3, 62.98 and 68.48 and 99.05 %
404 parasitemia suppression respectively and the results were highly significant(P <
405 0.001) compared to the negative control group at day-7.(see table 4)

406 Methanolic leaf crude extract of *C. molle* leaf at 100, 200, 400mg/kg/day showed
407 7.83±0.40 (P=0.997), 9.50±0.72 (P=0.248), 12.17±1.01 (P<0.001) and Chloroquine
408 base at 25mg/kg/day showed 28.83±0.65 (P<0.001) days of mean survival time in
409 curative test respectively. Crude methanolic extract 400mg/kg and Chloroquine base at
410 25mg/kg/day showed highly significant (P<0.001) in survival days compared to
411 negative controls (7.50±0.34)(see table 4).

412 **Table 4: Parasitaemia and percent parasitemia inhibition and survival date of *P.***
413 ***berghei* infected mice treated with crude methanolic extract of *C.molle* in the**
414 **Rane's (curative) test**

Extract	%Para Day 3	%Para Day4	%Para Day 5	% Para Day 6	Day 7		Av. Survival date
					%Para	% Parasitemia inhibition	
CON	22.73±0.84	24.95±0.92	27.55±0.73	32.68±0.29	38.76±0.82	0.00	7.50±0.34
CM ₁₀₀	24.77±0.72	24.58±0.73	23.72±0.65	22.77±0.67	21.98±0.76	43.3 ^{a3c3d3e3}	7.83±0.40 ^{d3e3}
CM ₂₀₀	22.33±0.60	23.02±0.48	20.48±0.65	17.37±0.79	14.35±1.01	62.98 ^{a3b3e3}	9.50±0.72 ^{c3}
CM ₄₀₀	22.57±0.48	23.32±0.50	17.77±0.49	14.03±0.54	12.22±0.49	68.48 ^{a3b3e3}	12.17±1.01 ^{a3b3e3}
CQ ₁₀	23.17±0.84	17.53±0.97	8.07±1.92	2.37±0.90	0.37±0.27	99.05 ^{a3b3c3d3}	28.83±0.65 ^{a3b3c3e3}


415 Data are expressed as mean ± SEM; n = 6: CQ = chloroquine, CON = Control, CM,
416 crude methanolic extract of *Combretum molle*, % par supp= % parasitemia
417 suppression, Numbers refer to dose in mg/kg. a, compared to neg. control; b, to
418 100mg/kg; c, to 200mg/kg; d, to 400 mg/kg; e, to CQ 25mg/kg: 1p<0.05, 2p<0.01,
419 3p<0.001.

420 *Plasmodium berghei* infected mice treated in a curative test at 100mg/kg/day methanol
421 crude extract increase a mean body weight of 2.41±1.912g (p = 0.011), 200mg/kg/day
422 loss mean body weight of 0.88±2.140g (P = 0.128), 400mg/kg/day loss mean body
423 weight of 4.38±1.014g (P= 0.697), and Chloroquine base at 25mg/kg/day loss mean
424 body weight of 2.42±0.927g (P= 0.315) and mice treated with solvent loss mean body
425 weight of 8.18±3.624g. (See figure 3A)

426 *Plasmodium berghei* infected mice treated in a curative test at 100mg, 200mg, 400mg
427 /kg/day methanol crude extract and Chloroquine base at 25mg/kg/day decrease a mean

428 body temperature of 0.95 ± 1.36 °C ($p = 0.673$), 0.73 ± 1.05 °C ($P = 0.991$), 1.01 ± 1.05 °C
 429 ($P = 0.998$) and 4.86 ± 1.48 °C ($P < 0.001$) and mice treated with solvent decrease a mean
 430 body temperature of 1.57 ± 1.63 °C. (See figure 3B)

431 *Plasmodium berghei* infected mice treated in a curative test at 100mg, 200mg, 400mg
 432 /kg/day methanol crude extract and Chloroquine base at 25mg/kg/day loss a mean
 433 packed cell volume of $6.65 \pm 1.89\%$ ($p = 0.001$), $5.41 \pm 0.84\%$ ($P < 0.001$), $0.53 \pm 1.24\%$
 434 ($P < 0.001$) and $1.02 \pm 0.45\%$ ($P < 0.001$) and mice treated with solvent loss a mean
 435 packed cell volume of $15.02 \pm 1.04\%$. The extract of *C.molle* leaf showed a significant
 436 difference in a mean packed cell volume compared to the negative control. (See figure
 437 3C)



438
 439 **Figure 3: Showed effect of Crude methanolic extract of *C. molle* leaf in *P. berghei***
 440 **infected mice in Curative test.** [CON = negative control (solvent 10ml/kg), CM=
 441 chloroform fraction, CQ = chloroquine, BWD0= body weight at day zero, BWD7=
 442 body weight at day 7, PCV= packed cell volume, numbers = dose in mg/kg/day]

443 Antimalarial repository test of methanolic crude extract of *C. molle* leaf and
 444 chloroquine base against *P.berghei* infected mice resulted in reduced parasite load as
 445 compared to their respective negative control group. Methanolic crude extract at 100,
 446 200 and 400mg/kg/day and Chloroquine base at 25mg/kg/day showed 51.00, 62.65,
 447 76.20 and 99.20% parasitemia suppression respectively and the results were highly
 448 significant($P < 0.001$) compared to the negative control group at day-7.(see table 5)

449 Methanolic leaf crude extract of *C. molle* leaf at 100, 200, 400mg/kg/day in repository
 450 test showed 7.50±0.99 (P=0.977), 10.00±2.31 (P=0.550), 17.67±3.05 (P=0.001) and
 451 Chloroquine base at 25mg/kg/day showed 29.00±0.63 (P<0.001) days of mean
 452 survival time in seven-day repository test respectively. Chloroquine base at
 453 25mg/kg/day showed highly significant (P<0.001) in survival days compared to
 454 negative controls 6.00±0.97 (see table 5).

455 **Table 5: Mean Percent Parasitemia and mean percent parasitemia suppression**
 456 **and mean survival time of *P. berghei* infected mice treated with methanolic crude**
 457 **extract of *C. molle* leaf in repository (prophylactic) test.**

Extract	% Parasitemia	% Parasitemia Suppression	Mean survival time
CON	24.90±2.16	0.00	6.00±0.97
CM ₁₀₀	12.20±0.41	51.00 ^{a3d2e3}	7.50±0.99 ^{d2e3}
CM ₂₀₀	9.30±0.56	62.65 ^{a3e3}	10.00±2.31 ^{d1e3}
CM ₄₀₀	5.93±0.49	76.20 ^{a3b2e2}	17.67±3.05 ^{a2b2c1e3}
CQ25	0.20±0.20	99.20 ^{a3b3c3d2}	29.00±0.63 ^{a3b3c3d3}


458 Data are expressed as mean ± SEM; n = 6: CQ = chloroquine, CON = Control, CM,
 459 crude methanolic extract of *Combretum molle*, % par supp= % parasitemia
 460 suppression, Numbers refer to dose in mg/kg. a, compared to neg. control; b, to
 461 100mg/kg; c, to 200mg/kg; d, to 400 mg/kg; e, to CQ 25mg/kg: 1p<0.05, 2p<0.01,
 462 3p<0.001.

463 *Plasmodium berghei* infected mice treated in a repository test at 100mg/kg/day
 464 methanol crude extract of *C. molle* increase a mean body weight of 0.37±1.39g (p =
 465 1.000), 200mg/kg/day increase mean body weight of 1.84±1.08g (P = 0.665),
 466 400mg/kg/day increase mean body weight of 0.56±0.67g (P= 0.988), and Chloroquine
 467 base at 25mg/kg/day increase mean body weight of 0.08±0.93g (P = 1.000) and mice
 468 treated with solvent loss mean body weight of 0.15±1.01g. (See figure 4A)

469 *Plasmodium berghei* infected mice treated in a repository at 100mg, 200mg, 400mg
 470 /kg/day methanol crude extract of *C. molle* and Chloroquine base at 25mg/kg/day
 471 increase a mean body temperature of 0.75±0.30°C (p = 0.009), 0.27±0.41°C (P =
 472 0.149), 0.62±0.12°C (P< 0.021) and 0.75±0.16°C (P=0.009) and mice treated with
 473 solvent decrease a mean body temperature of 0.67±0.27°C. (See figure 4B)

474 *Plasmodium berghei* infected mice treated in a repository at 100mg, 200mg, 400mg
 475 /kg/day methanol crude extract of *C. molle* decrease a mean packed cell volume of
 476 3.25±0.95% (p = 0.998), 1.25±0.85% (P =0.984) and 9.40±12.23%, (P=0.995)

477 respectively and Chloroquine base at 25mg/kg/day decrease a mean packed cell
 478 volume of $0.50 \pm 0.56\%$ ($P=0.934$) and mice treated with solvent increase a mean
 479 packed cell volume of $6.00 \pm 0.41\%$. (See figure 4C)



480
 481 **Figure 4: Showed effect of Crude methanolic extract of *C. molle* leaf in *P. berghei***
 482 **infected mice in prophylactic test.** [CON = negative control (solvent 10ml/kg), CM=
 483 chloroform fraction, CQ = chloroquine, BWD0= body weight at day zero, BWD7=
 484 body weight at day 7, PCV= packed cell volume, numbers = dose in mg/kg/day]

485 Discussion

486 The rodent malaria model in mice is the most extensively used, and ideal for the
 487 primary *in vivo* tests of new antimalarials. Mice are easy to raise, maintain, handle,
 488 and are small (20-30g), thus requiring a small amount of drugs compared to chickens,
 489 rats or monkeys. Mice are also susceptible to several species of malaria parasites
 490 isolated in other rodent species. Mice may develop acute fulminating diseases induced
 491 by blood-stage parasites, or by sporozoites injected either by mosquito bites or
 492 intravenously, being excellent models for testing new drugs.^[11]

493 The leaf of *C. molle* methanolic crude extract phytochemical screening showed the
 494 presence of secondary metabolites: alkaloids, Cardiac glycosides, flavonoids, phenols,
 495 saponnins, tannins and terpenoids by using specific chemicals and methods ^[23]. These

496 compounds are known to show curative activity against several ailments in man and
497 therefore could explain the traditional use of medicinal plants for the treatment of
498 some illnesses [29, 30, 31].

499 Crude Methanolic extract was non-toxic to test mice, as they did not show signs of
500 acute toxicity for 14 days at the doses of 2000mg/kg body weight, thus the traditional
501 use of the plant material by local people like the decoction of root, leaf, and fruit could
502 be safe provided that the amount used is in the ranges tested in this study. However,
503 species variation would also limit such a straight forward extrapolation of the findings
504 of this study to humans.

505 The subacute toxicity evaluation of *C. molle* crude methanolic leaf extract showed a
506 mean body weight decrease from week 0 to week 4 in a decreasing order from
507 100mg/kg/day to 400mg/kg/day and mice treated with the solvent showed a mean
508 weight gain from week 0 to week 4.

509 The mean weight of kidneys of mice treated with the three different doses of *C.molle*
510 methanolic crude leaf extract in subacute toxicity evaluation did not show any
511 significant difference compared to the negative control.

512 The mean weight of liver of mice treated with the three different doses of *C.molle*
513 methanolic crude leaf extract in subacute toxicity evaluation showed significant
514 differences at 200mg/kg/day and 400mg/kg/day compared to the negative control.

515 The histopathological examination of liver and kidney tissues in subacute toxicity of
516 mice treated with 100, 200, and 400mg/kg/day body weight of *C. Molle* crude
517 methanolic leaf extract showed normal histological structures similar to the negative
518 control group.

519 The crude methanolic extract of dried stem of *C. molle* in *In vitro* cell culture with
520 *plasmodium falciparum* also showed an activity with IC₅₀ value of 1.25 µg/ML [20, 21].

521 So the methanolic crude extract obtained from *C. molle* showed high *in vitro* activity
522 which helps to proceed *in vivo* study. Therefore, the present study was carried out on
523 *in vivo* antimalarial study of the methanolic crude extract of *C. molle* leaf in
524 *Plasmodium berghei* infected mice. Methanol crude extract showed dose-dependent
525 activity against *plasmodium berghei* in a 4-day suppressive test. In comparing the
526 result obtained from the present study the three doses of crude methanolic extract

527 showed significant parasitemia suppression compared to the negative control. *In vivo*
528 antiparasmodial activity can be classified as moderate, good, and very good if an extract
529 displayed percent parasite suppression equal to or greater than 50% at a dose of 500,
530 250 and 100mg/kg body weight per day respectively ^[12]. Based on this classification,
531 the methanolic crude extract at 200 and 400 mg/kg/day showed 45.36% and 76.17 %
532 suppression against *P. berghei* in mice respectively and exhibited good to moderate
533 antiparasmodial activity. These result indicated that compounds which have
534 antimalarial activity were soluble in the solvent used to extract.

535 The crude methanolic extract of *C.molle* in a four day suppressive test at all doses did
536 not produce significant difference in body weight and packed cell volume compared to
537 the negative control but they produce significant difference (P< 0.003) from
538 200mg/kg/day in reducing body temperature. The crude methanolic extract at doses of
539 100, 200 and 400mg/kg/day showed increased mean survival time compared to the
540 negative control but didn't produce a significant difference from the negative control.
541 Mice treated with chloroquine base 25mg/kg/day showed a significant difference
542 compared to the negative control.

543 In the curative test the average percent parasitemia was increased in the negative
544 control from 3rd day to the 7th day. The *Plasmodium berghei* infected mice treated
545 with crude extract the average percent parasitemia increased from the day -3 to day -4
546 and showed a decrease in percent parasitemia from the day-5 to day -7 in a dose-
547 dependent manner compared to the negative control. The infected mice treated with
548 Chloroquine base showed a decrease in average percent parasitemia from 3rd day to the
549 7th day.

550 In the curative test crude methanolic extract of *C. molle* produced significant
551 difference in percent packed cell volume compared to the negative control. The crude
552 methanolic extract at doses of 100, 200 and 400mg/kg/day showed increased mean
553 survival time compared to the negative control and but only produced significant
554 difference at 400mg/kg/day compared to negative control.

555 Methanolic crude extract in repository(prophylactic) test at 100, 200 and
556 400mg/kg/day and Chloroquine bate at 25mg/kg/day showed 51.00, 62.65, 76.20 and

557 99.20% parasitemia suppression respectively and the results were highly significant(P
558 < 0.001) compared to the negative control group at day-7.

559 The promising result from the curative and prophylactic tests suggests that the crude
560 extract has therapeutic efficacy against established malarial parasitic infections. The
561 observed significant percent parasitemia inhibition, prevention of body weight
562 reduction, increase in packed cell volume, body temperatue and mean survival time in
563 four-day suppressive test and observed curative potential in established *Plasmodium*
564 *bergei* infection were expected to be from the effects of the secondary metabolites
565 such as Inhibition of extracellular microbial enzymes, deprivation of the substrates
566 required for microbial growth or direct action on microbial metabolism through
567 inhibition of oxidative phosphorylation^[25]. Intercalation of DNA and inhibition of
568 DNA synthesis through topoisomerase inhibition and termination of cell division,
569 complexion with extracellular and soluble proteins and disruption of microbial
570 membranes, enzymes, hydrogen bonding and hydrophobic effects, as well as by
571 covalent bond formation, inactivation of microbial adhesins, enzymes, cell envelope
572 transport proteins^[27]. Inhibiting growth, and protease activity ^[29]. Capable of
573 precipitating gelatinous compounds, phagocytic cells, host-mediated tumor activity
574 ^[30].

575 **Conclusion**

576 The present study indicates that 80% methanolic crude extract of *Combretum molle*
577 leaf has good antimalarial on the measured parameters. The crude methanolic extract
578 showed significant parasitemia suppression and mean survival time in the 4-day
579 Chemosuppressive, curative and prophylaxis tests but other parameters such as
580 prevention in a reduction of body weight, body temperature, in protecting infected
581 animals from parasite-induced PCV reduction were not significantly different
582 compared to the negative control. The subacute toxicity evaluations showed no
583 toxicity at the three different doses in histopathological examination. Findings suggest
584 that the phytochemicals responsible for antimalarial activity of the plant are soluble in
585 80% methanol which upholds the earlier in vitro findings as well as the folkloric use in
586 Ethiopian traditional medicine.

587 **Recommendation**

588 We forward the recommendation for investigators to carry out in-depth study to
589 isolate, identify and characterize the bioactive constituents responsible for antimalarial
590 activity of leaf of the *C.molle*. In the present study acute and sub-acute toxicity was
591 done showing that the plant was safe. Therefore, we recommend performing chronic
592 histopathological and biochemical toxicity study of the plant.

593 **Ethical approval:**

594 The animals were handled according to the governance of animal care and use for
595 scientific purposes in Africa and the Middle East [33]. And the ethical clearance was
596 requested and obtained from the Department of Pharmacology, School of
597 Pharmacy, University of Gondar for the use of animals for experiment with Ref.
598 No. 5094/96/2011. And the research was performed as per the agreement.

599 **List of abbreviations:** Not applicable

600 **Consent to publish:** Not applicable

601 **Availability of data and material:** All data generated or analyzed during this study
602 have been attached on the supplementary material.

603 **Competing interests**

604 The authors declare that they have no competing interest to disclose.

605 **Funding:** No source of funding

606 **Authors' contributions**

607 MA was involved in developing the proposal and designing of the study. MA, GM, TJ,
608 and EF conducted the actual study and the statistical analysis and in the write up of the
609 manuscript was done by MA and TJ. All authors gave the final approval of the version
610 to be published, and agree to be accountable for all aspects of the work.

611 **Acknowledgment**

612 We are very grateful to University of Gondar for the approval of the ethical clearance,
613 laboratory facility, and authentication of the plant material and for their technical
614 supports. Lastly, we would like to thank the Ethiopian public health institute for the
615 free delivery of *P. berghei* parasite.

616 **References**

617 1. Buffet PA, Safeukui I, Deplaine G, Brousse V, Prendki V, Thellier M, Turner GD,
618 Mercereau-Puijalon O. The pathogenesis of Plasmodium falciparum malaria in

- 619 humans: insights from splenic physiology. *Blood, Journal of the American Society*
620 *of Hematology*. 2011 Jan 13;117(2):381-92.[[Google Scholar](#)]
- 621 2. Cowman AF, Crabb BS. Invasion of red blood cells by malaria parasites. *Cell*. 2006
622 Feb 24;124 (4):755-66. [[Google Scholar](#)]
- 623 3. Lee RS, Waters AP, Brewer JM. A cryptic cycle in haematopoietic niches promotes
624 initiation of malaria transmission and evasion of chemotherapy. *Nature*
625 *communications*. 2018 Apr 27;9 (1):1-9. [[Google Scholar](#)]
- 626 4. Cohuet A, Harris C, Robert V, Fontenille D. Evolutionary forces on Anopheles:
627 what makes a malaria vector?. *Trends in parasitology*. 2010 Mar 1;26(3):130-6.
628 [[Google scholar](#)]
- 629 5. Reyburn H. New WHO guidelines for the treatment of malaria. *BMJ (Clinical*
630 *research ed)*. 2010; 340:c2637. [[Google scholar](#)]
- 631 6. Zhang Y, Xie L, Xie L, Bourne P. The Plasmodium falciparum drugome and its
632 polypharmacological implications. *bioRxiv*. 2016 Jan 1:042481. [[Google scholar](#)]
- 633 7. White NJ. Counter perspective: artemisinin resistance: facts, fears, and fables. *The*
634 *American journal of tropical medicine and hygiene*. 2012 Nov 7; 87(5):785.[[Google](#)
635 [scholar](#)]
- 636 8. WHO: World malaria report 2018. ISBN 978-92-4-156565-3
- 637 9. Guerra CA, Snow RW, Hay SI. Mapping the global extent of malaria in 2005.
638 *Trends in parasitology*. 2006 Aug 1;22(8):353-8.[[Google scholar](#)]
- 639 10. Lai S, Sun J, Ruktanonchai NW, Zhou S, Yu J, Routledge I, Wang L, Zheng Y,
640 Tatem AJ, Li Z. Changing epidemiology and challenges of malaria in China
641 towards elimination. *Malaria journal*. 2019 Dec;18(1):107.[[Google scholar](#)]
- 642 11. Rogerson SJ, Mwapasa V, Meshnick SR. Malaria in pregnancy: linking immunity
643 and pathogenesis to prevention. In *Defining and Defeating the Intolerable Burden of*
644 *Malaria III: Progress and Perspectives: Supplement to Volume 77 (6) of American*
645 *Journal of Tropical Medicine and Hygiene* 2007 Dec. *American Society of Tropical*
646 *Medicine and Hygiene*. [[Google Scholar](#)]
- 647 12. Woime AW. *Changes in the spread of malaria in Ethiopia: case study from Awassa*
648 *and Hossana area 2006-2007* (Master's thesis, *Høgskolen i Telemark*). [[Google](#)
649 [scholar](#)]

- 650 13. Deressa W, Olana D, Chibsa S. Magnitude of malaria admissions and deaths at
651 hospitals and health centers in Oromia, Ethiopia. *Ethiopian medical journal*. 2004
652 Oct;42(4):237-46.[[Google scholar](#)]
- 653 14. STACE CA. The significance of the leaf epidermis in the taxonomy of the
654 Combretaceae: I. A general review of tribal, generic and specific characters.
655 *Journal of the Linnean Society of London, Botany*. 1965 Jul;59(378):229-
656 52.[[Google scholar](#)]
- 657 15. Lima GR, de Sales IR, Caldas Filho MR, de Jesus NZ, Falcão HD, Barbosa-Filho
658 JM, Cabral AG, Souto AL, Tavares JF, Batista LM. Bioactivities of the Genus
659 Combretum (Combretaceae): A Review. *Molecules*. 2012 Aug 1;17(8).[[Google](#)
660 [scholar](#)]
- 661 16. Keay RW. Trees of Nigeria. *Clarendon Press*; 1989.[[Google scholar](#)]
- 662 17. Mesfin F, Seta T, Assefa A. An ethnobotanical study of medicinal plants in Amaro
663 Woreda, Ethiopia. *Ethnobotany Research and Applications*. 2014 Sep 6;12:341-
664 54.[[Google Scholar](#)]
- 665 18. Meragiaw M, Asfaw Z, Argaw M. The status of ethnobotanical knowledge of
666 medicinal plants and the impacts of resettlement in Delanta, northwestern Wello,
667 northern Ethiopia. *Evidence-Based Complementary and Alternative Medicine*.
668 2016;2016.[[Google Scholar](#)]
- 669 19. Asres K, Balcha F. Phytochemical screening and in vitro antimalarial activity of the
670 stem bark of Combretum molle R. Br ex G Don *Ethiopian Pharm J*. 1998;16:25-
671 33.[[Google Scholar](#)]
- 672 20. Atindehou KK, Schmid C, Brun R, Koné MW, Traore D. Antitrypanosomal and
673 antiplasmodial activity of medicinal plants from Côte d'Ivoire. *Journal of*
674 *Ethnopharmacology*. 2004 Feb 1;90(2-3):221-7.[[Google Scholar](#)]
- 675 21. Gansané A, Sanon S, Ouattara LP, Traoré A, Hutter S, Ollivier E, Azas N, Traore
676 AS, Guissou IP, Sirima SB, Nebié I. Antiplasmodial activity and toxicity of crude
677 extracts from alternatives parts of plants widely used for the treatment of malaria in
678 Burkina Faso: contribution for their preservation. *Parasitology research*. 2010 Jan
679 1;106(2):335.

- 680 22. Al-Adhroey AH, Nor ZM, Al-Mekhlafi HM, Amran AA, Mahmud R. Antimalarial
681 activity of methanolic leaf extract of Piper betle *L. Molecules*. 2011 Jan;16(1):107-
682 18.[[Google Scholar](#)]
- 683 23. Zohra SF, Meriem B, Samira S, Muneer MA. Phytochemical screening and
684 identification of some compounds from mallow. *J Nat Prod Plant Resour*.
685 2012;2(4):512-6. [[Google Scholar](#)].
- 686 24. Alafid F, Edrah SM, Meelad FM, Belhaj S, Altwair K, Maizah NR. Evaluation of
687 phytochemical constituents and antibacterial activity of thymelaea hirsuta (l.) Endl,
688 and that utilised as a conventional treatment of infertility and diabetic in Libya.
689 *World Journal of Pharmaceutical Research*. 2019, 8(11), 72 - 88 [[Google Scholar](#)].
- 690 25. Scalbert A. Antimicrobial properties of tannins. *Phytochemistry*. 1991;30(12):3875-
691 83.[[Abstract](#), [Google Scholar](#)].
- 692 26. Usman H, Abdulrahman FI, Usman A. Qualitative phytochemical screening and in
693 vitro antimicrobial effects of methanol stem bark extract of *Ficus thonningii*
694 (Moraceae). *Afr. J. Trad. CAM*. 2009, 6 (3): 289 – 295. [[Google Scholar](#)].
- 695 27. Cowan MM. Plant products as antimicrobial agents. *Clinical microbiology reviews*.
696 1999 ;12(4):564-82. [[Google Scholar](#)].
- 697 28. Dibua Uju Marie-Esther, Okeke Chioma Concilia, Ugwu Chioma, Kenechukwu
698 Franklin Chimaobi and Okorie Austin. *In vivo* antimalarial and cytotoxicity activity
699 of ethanolic stem bark of *Petersianthus macrocarpus* and leaf of *Astonia boonei* in
700 experimental mice model. *Int.J.Curr.Microbiol.App.Sci*. 2013, 2(12): 354-368.
701 [[Google Scholar](#)].
- 702 29. Othman L, Sleiman A, Abdel-Massih RM. Antimicrobial Activity of Polyphenols
703 and Alkaloids in Middle Eastern Plants. *Frontiers in microbiology*. 2019; 10: 911.
704 [[Google Scholar](#)].
- 705 30. Omojate Godstime C, Enwa Felix O, Jewo Augustina O, Eze Christopher O.
706 Mechanisms of antimicrobial actions of phytochemicals against enteric pathogens—a
707 review. *J Pharm Chem Biol Sci*. 2014; 2(2):77-85. [[Google Scholar](#)].
- 708 31. Gollapudi S, Sharma HA, Aggarwal S, Byers LD, Ensley HE, Gupta S. Isolation of
709 a previously unidentified polysaccharide (MAR-10) from *Hyssop officinalis* that
710 exhibits strong activity against human immunodeficiency virus type 1. *Biochemical*

- 711 *and biophysical research communications*. 1995 May 5; 210(1):145-51. [[Google](#)
712 [Scholar](#)].
- 713 32. OECD Guidelines for the Testing of Chemicals are periodically reviewed in the
714 light of scientific progress or changing assessment practices; 2001, number 425.
715 [[Google Scholar](#)].
- 716 33. Mohr BJ, Fakoya FA, Hau J, Souilem O, Anestidou L. The governance of animal
717 care and use for scientific purposes in Africa and the Middle East. *ILAR Journal*.
718 2016, 57(3), 333–346. [[Google Scholar](#)].
- 719 34. Parasuraman S. Toxicological screening. *Journal of pharmacology &*
720 *pharmacotherapeutics*. 2011; 2(2):74 - 79. [[Google Scholar](#)].
- 721 35. Ryley JF, Peters W. The antimalarial activity of some quinolone esters. *Annals of*
722 *Tropical Medicine & Parasitology*. 1970 Jun 1;64(2):209-22.[[Google Scholar](#)].
- 723 36. Gurney PC, Elliott SS, Vom E, Spence SJ, Bagnato S, Watkins A, inventors; Leica
724 Biosystems Melbourne Pty Ltd, assignee. Method and Apparatus for Tissue Sample
725 Processing. *United States patent application US 11/867,760*. 2008 May 15.[[Google](#)
726 [Scholar](#)].
- 727 37. Hegazy R. Hegazy'simplified method of tissue processing (consuming time and
728 chemicals). *Annals of International Medical and Dental Research*.
729 2015;1(2):57.[[Google Scholar](#)]
- 730 38. Chong WC, Wu R, Tu AY. A study on tissue processing. *International Journal of*
731 *Innovative Interdisciplinary Research*. 2012; 1:37-43.[[Google Scholar](#)]
- 732 39. Fidock DA, Rosenthal PJ, Croft SL, Brun R, Nwaka S. Antimalarial drug
733 discovery: efficacy models for compound screening. Supplementary documents.
734 *Trends Parasitol*. 2004;15:19-29.[[Google scholar](#)]
- 735 40. Bantie L, Assefa S, Teklehaimanot T, Engidawork E. In vivo antimalarial activity
736 of the crude leaf extract and solvent fractions of *Croton macrostachyus*
737 *Hocsht.*(Euphorbiaceae) against *Plasmodium berghei* in mice. *BMC complementary*
738 *and alternative medicine*. 2014;14(1):79.[[Google Scholar](#)]
- 739 41. Asefa A, Urga K, Guta M, Mekonene W, Melaku D, Mudie K, Kidanemariam T. *In*
740 *vivo* antimalarial activities of plants used in Ethiopian traditional medicine,

- 741 Delomenna, Southeast Ethiopia. *Ethiopian Journal of Health Sciences*. 2007; 17(2),
742 81 – 89. [[Google Scholar](#)].
- 743 42. Iyiola OA, Tijani AY, Lateef KM. Antimalarial activity of ethanolic stem bark
744 extract of *Alstonia boonei* in mice. *Asian J. Biol. Sci.* 2011; 4:235-43. [[Google](#)
745 [Scholar](#)].
- 746 43. Fidock DA, Rosenthal PJ, Croft SL, Brun R, Nwaka S. Antimalarial drug
747 discovery: efficacy models for compound screening. *Nature reviews Drug*
748 *discovery*. 2004; 3(6):509 - 520.[[Google Scholar](#)]
- 749 44. Fentahun S, Makonnen E, Awas T, Giday M. In vivo antimalarial activity of crude
750 extracts and solvent fractions of leaves of *Strychnos mitis* in *Plasmodium berghei*
751 infected mice. *BMC complementary and alternative medicine*. 2017
752 Dec;17(1):13.[[Google Scholar](#)]
- 753 45. Birru EM, Geta M, Gurmu AE. Antiplasmodial activity of *Indigofera spicata* root
754 extract against *Plasmodium berghei* infection in mice. *Malaria journal*. 2017
755 Dec;16(1):198.[[Google Scholar](#)]
- 756 46. Dhanabalan R, Balachandar S, Devakumar J, Sreeraj B, Chandni JN. In vivo
757 antiplasmodial activity of medicinal plants used in pyrexia among ethnic
758 communities of Western Ghats, Coimbatore, Tamil Nadu. *Journal of Pharmacy*
759 *Research*. 2018; 12(4):541.[[Google](#)

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [DrugsChemicalsandmaterials.docx](#)
- [CrudedataofMethanolicextractofC.molleleaf.xlsx](#)